AU5617900A - Chimeric chemokine-antigen polypeptides and uses therefor - Google Patents

Chimeric chemokine-antigen polypeptides and uses therefor

Info

Publication number
AU5617900A
AU5617900A AU56179/00A AU5617900A AU5617900A AU 5617900 A AU5617900 A AU 5617900A AU 56179/00 A AU56179/00 A AU 56179/00A AU 5617900 A AU5617900 A AU 5617900A AU 5617900 A AU5617900 A AU 5617900A
Authority
AU
Australia
Prior art keywords
uses therefor
antigen polypeptides
chimeric chemokine
chemokine
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56179/00A
Inventor
Robert C. Gallo
Alfredo Garzino-Demo
Siew Pheng Lim
Yin Hwee Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Molecular and Cell Biology
University of Maryland Biotechnology Institute UMBI
Original Assignee
Institute of Molecular and Cell Biology
University of Maryland Biotechnology Institute UMBI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Molecular and Cell Biology, University of Maryland Biotechnology Institute UMBI filed Critical Institute of Molecular and Cell Biology
Publication of AU5617900A publication Critical patent/AU5617900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
AU56179/00A 1999-06-17 2000-06-16 Chimeric chemokine-antigen polypeptides and uses therefor Abandoned AU5617900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33515099A 1999-06-17 1999-06-17
US09335150 1999-06-17
PCT/US2000/016598 WO2000078334A1 (en) 1999-06-17 2000-06-16 Chimeric chemokine-antigen polypeptides and uses therefor

Publications (1)

Publication Number Publication Date
AU5617900A true AU5617900A (en) 2001-01-09

Family

ID=23310491

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56179/00A Abandoned AU5617900A (en) 1999-06-17 2000-06-16 Chimeric chemokine-antigen polypeptides and uses therefor

Country Status (2)

Country Link
AU (1) AU5617900A (en)
WO (1) WO2000078334A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2006033665A1 (en) 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
AU2001291049A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
US7897152B2 (en) 2000-09-18 2011-03-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-antigen fusion proteins
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
FR2828404B1 (en) * 2001-08-10 2005-07-15 Neovacs COMPOSITE SUPERIMMUNOGEN FOR BIFUNCTIONAL VACCINE USE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH STROMAL TISSUE DISORDER
AU2002217820A1 (en) * 2001-09-17 2003-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection
IL162600A0 (en) * 2001-12-17 2005-11-20 Applied Research Systems Cc-chemokine mutants as cc-chemokine antagonists
CA2640066A1 (en) * 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
JP2013540700A (en) * 2010-08-09 2013-11-07 サイバツクス・インコーポレイテツド Methods and compositions for preventing disease
DK2643345T5 (en) * 2010-11-25 2021-05-17 Imnate Sarl IMMUNOGENIC PEPTIDES FOR USE FOR PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, immune responses to ALLOFAKTORER, ALLERGY DISEASES, TUMORS, transplant rejection and immune responses to viral vectors USED FOR GENE THERAPY OR gene vaccination
US9156900B2 (en) 2011-03-31 2015-10-13 Riken Control agent for controlling undifferentiated state and use thereof
WO2013041966A1 (en) * 2011-09-23 2013-03-28 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
WO2014028644A1 (en) * 2012-08-15 2014-02-20 Cyvax, Inc. Methods and compositions for preventing a condition
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
AU2016322506B2 (en) * 2015-09-16 2023-02-09 Io Biotech Aps Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
AU2020243431A1 (en) 2019-03-18 2021-09-30 Ludwig Institute For Cancer Research Ltd. A2/NY-ESO-1 specific T cell receptors and uses thereof
CN113151184B (en) * 2020-06-15 2023-03-21 上海市公共卫生临床中心 Method for cell membrane-based display of coronavirus immunogens to induce neutralizing antibodies
WO2023288203A2 (en) 2021-07-12 2023-01-19 Ludwig Institute For Cancer Research Ltd T cell receptors specific for tumor-associated antigens and methods of use thereof
WO2023222829A1 (en) 2022-05-17 2023-11-23 Centre Hospitalier Universitaire Vaudois Designed biosensors for enhanced t cell therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
DE69523857T2 (en) * 1994-09-16 2002-06-13 Merck Patent Gmbh immunoconjugates

Also Published As

Publication number Publication date
WO2000078334A1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
AU1685600A (en) Polypeptides
AU6241698A (en) Tace-like and matrilysin-like polypeptides
AU6058500A (en) Fusion protein and uses thereof
AU5617900A (en) Chimeric chemokine-antigen polypeptides and uses therefor
AU7469998A (en) Chimeric opg polypeptides
AUPQ976800A0 (en) Novel polypeptides and polynucleotides and uses therefor
AU3751000A (en) Chimeric toxins
AU5179400A (en) Switching complex architecture and operation
AU5043200A (en) Adam polynucleotides and polypeptides
AU4776800A (en) Acetylcholinesterase-derived peptides and uses thereof
AU1077200A (en) Novel chimeric polypeptide
AU5706000A (en) Useful polypeptide
AU5994599A (en) Rbp1 polypeptides and uses thereof
AU2399601A (en) Novel tachykinin-like polypeptides and use thereof
AU2691500A (en) Novel polypeptide
AU2136401A (en) P450rai-2 and related proteins
AU6983000A (en) Chimeric proteins
GB9917165D0 (en) Polypeptides polynuclcotides and uses thereof
AU4778600A (en) Novel polypeptide
AU5979300A (en) Angiopoietin-6 and uses thereof
AU6712600A (en) Polypeptides
AU1228201A (en) Umlr polypeptides
AU2002218199A1 (en) Truncated phosphodiesterase-7 polypeptides
AU1686701A (en) Dispatched polypeptides
AU2109200A (en) Polypeptide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase